Huadong Medicine (HD Medicine) (000963.SZ)

Executive Summary

Huadong Medicine (HD Medicine) is a leading Chinese pharmaceutical company with a market capitalization of approximately $8.9 billion, listed on the Shenzhen Stock Exchange (Ticker: 000963.SZ). Headquartered in Hangzhou, the company focuses on the development and commercialization of innovative medicines across multiple therapeutic areas, including metabolic diseases, oncology, and autoimmune disorders. With a robust portfolio of over 10 commercial products and a strong R&D pipeline, Huadong Medicine has established itself as a key player in China's rapidly expanding pharmaceutical market. The company's strategy emphasizes in-house innovation, strategic partnerships, and manufacturing excellence, positioning it for sustained growth amid China's healthcare reforms and increasing demand for novel therapies. Recent investments in cutting-edge technologies, such as GLP-1 receptor agonists and targeted cancer therapies, underscore its commitment to addressing unmet medical needs in both domestic and global markets.

Upcoming Catalysts (preview)

• Q3 2026NDA submission for innovative GLP-1 analog for type 2 diabetes80% success
• Q4 2026Phase 3 topline data readout for novel oncology drug candidate70% success
• TBDStrategic licensing deal for biosimilar or next-generation biologic60% success